Skip to main content

Advertisement

SpringerLink
Log in

A Perspective on inflammatory bowel disease in the child and adolescent at the turn of the millennium

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

The literature of the past year has produced significant advances relevant to the diagnosis and treatment of children and adolescents with inflammatory bowel disease. This review focuses on new observations regarding the epidemiology, genetics, etiology, diagnosis, and treatment of both Crohn’s disease and ulcerative colitis in children. Particular attention is paid to the expanded indications for the use of immunomodulatory therapy, and to the early published data regarding the safety and efficacy of treatment with infliximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lindberg E, Lindquist B, Holmquist L, Hildebrand H: Inflammatory bowel disease in children and adolescents in Sweden, 1984–1995. J Pediatr Gastrenterol Nutr 2000, 20:259–264.

    Article  Google Scholar 

  2. Mellemkjaer L, Johansen C, Gridley G, et al.: Crohn’s disease and cancer risk (Denmark). Cancer Causes Control 2000,11:145–150.

    Article  PubMed  CAS  Google Scholar 

  3. Ekbom A, Helmick C, Zack M, Adami H-O: Increased risk of large bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990, 336:357–359.

    Article  PubMed  CAS  Google Scholar 

  4. Greenstein AJ, Gennuso R, Sachar DB, et al.: Extraintestinal cancers in inflammatory bowel disease. Cancer 1985, 56:2914–2921.

    Article  PubMed  CAS  Google Scholar 

  5. Orholm M, Fonager K, Sorensen HT: Risk of ulcerative colitis and Crohn’s disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 1999, 94:3236–3238.

    Article  PubMed  CAS  Google Scholar 

  6. Sutton CL, Yang H, Li Z, et al.: Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut 2000;46:58–63.

    Article  PubMed  CAS  Google Scholar 

  7. Brant SR, Panhuysen CIM, Bailey-Wilson JE, et al.: Linkage heterogeneity for the IBD1 locus in Crohn’s disease pedigrees by disease onset and severity. Gastroenterology 2000, 119:1483–1490.

    Article  PubMed  CAS  Google Scholar 

  8. Wakefield AJ, Ekbom A, Dhillon AP, et al.: Crohn’s disease: pathogenesis and persistent measles virus infection. Gastroenterology 1995, 108:911–916.

    Article  PubMed  CAS  Google Scholar 

  9. Folwaczny C, Loeschke K, Schnettler D, et al.: Endothelial cell autoantibodies are a marker of disease susceptibility in inflammatory bowel disease but apparently not linked to persistent measles virus infection. Clin Immunol 2000, 95:197–202.

    Article  PubMed  CAS  Google Scholar 

  10. Pardi DS, Tremaine WJ, Sandborn WJ, et al.: Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol 2000, 95:1480–1485.

    Article  PubMed  CAS  Google Scholar 

  11. Kawashima H, Mori T, Kashiwagi Y, et al.: Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci 2000, 45:723–729.

    Article  PubMed  CAS  Google Scholar 

  12. Irvine EJ, Marshall JK: Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk. Gastroenterology 2000, 119:1740–1744. This case report provides data supporting the hypothesis that increased gut permeability is a seminal event in the pathogenesis of Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  13. Cucchiara S, Celentano L, de Magistris TM, et al.: Colonoscopy and technetium-99m white cell scan in children with suspected inflammatory bowel disease. J Pediatr 1999, 135:727–732.

    Article  PubMed  CAS  Google Scholar 

  14. Charron M, Di Lorenzo C, Kocoshis S: Are 99mTc leukocyte scintigraphy useful in children suspected of having inflammatory bowel disease? Am J Gastroenterol 2000, 95:1208–1212.

    Article  PubMed  CAS  Google Scholar 

  15. Gibson J, Neilly JB, Wray APM, et al.: 99Tcm-HMPAO leukocyte labelling in orofacial granulomatosis and gastrointestinal Crohn’s disease in childhood and early adulthood. Nucl Med Commun 2000, 21:155–158.

    Article  PubMed  CAS  Google Scholar 

  16. Ruess L, Blask AR, Bulas DI, et al.: Inflammatory bowel disease in children and young adults: correlation of sonographic and clinical parameters during treatment. AJR Am J Roentgenol 2000, 175:79–84.

    PubMed  CAS  Google Scholar 

  17. Durno CA, Sherman P, Williams T, et al.: Magnetic resonance imaging to distinguish the type and severity of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2000, 30:170–174.

    Article  PubMed  CAS  Google Scholar 

  18. Farrell RJ, Murphy A, Long A, et al.: High multi-drug resistance (P-Glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000,118:279–288.

    Article  PubMed  CAS  Google Scholar 

  19. Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000, 6:48–57.

    Article  PubMed  CAS  Google Scholar 

  20. Markowitz J, Grancher K, Kohn N, et al., and the Pediatric Collaborative Group: The multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterol 2000, 119:895–902. Report from a prospective, collaborative, placebo-controlled trial that establishes the efficacy of 6-MP as an initial therapy for children with moderate to severe Crohn’s disease activity at the time of diagnosis.

    Article  CAS  Google Scholar 

  21. Jeshion WC, Larsen KL, Jawad AF, et al.: Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn’s disease in children. J Clin Gastroenterol 2000, 30:295–298.

    Article  Google Scholar 

  22. Han PD, Lichtenstein GR, Jeshion WC, et al.: Preoperative therapy with 6-mercaptopurine predicts early recurrence following surgical resection for Crohn’s disease in children [abstract]. J Pediatr Gastroenterol Nutr 1997, 25:451.

    Google Scholar 

  23. Kader HA, Raynor SC, Young R, et al.: Introduction of 6-mercaptopurine in Crohn’s disease patients during the perioperative period: a preliminary evaluation of recurrence of disease. J Pediatr Gastoenterol Nutr 1997, 25:93–97.

    Article  CAS  Google Scholar 

  24. Korelitz B, Hanauer S, Rutgeerts, et al.: Post-operative prophylaxis with 6-MP, 5-ASA, or placebo in Crohn’s disease: a two year multicenter trial [abstract]. Gastroenterology 1998, 114:A1011.

    Article  Google Scholar 

  25. Kader HA, Mascarenhas MR, Piccoli DA, et al.: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999, 28:54–58.

    Article  PubMed  CAS  Google Scholar 

  26. Yates CR, Krynetski EY, Loennechen T, et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126:608–614.

    PubMed  CAS  Google Scholar 

  27. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713. This study establishes the usefulness of measuring TPMT genotype to identify patients at risk for toxicity during treatment with 6-MP or azathioprine. It also provides evidence supporting the measurement of 6-MP metabolite levels as a means of optimizing treatment response and minimizing toxicity.

    Article  PubMed  CAS  Google Scholar 

  28. Colombel JF, Ferrari N, Debuysere, et al.: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025–1030.

    Article  PubMed  CAS  Google Scholar 

  29. Bouhnik Y, Lemann M, Mary JY, et al.: Long-term follow-up of patients with Crohn’s disease treated with azathioprine and 6-mercaptopurine. Lancet 1996, 347:215–219.

    Article  PubMed  CAS  Google Scholar 

  30. Kim PS, Zlatanic J, Korelitz BI, Gleim GW: Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol 1999, 94:3254–3257.

    Article  PubMed  CAS  Google Scholar 

  31. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998,115:813–821. A retrospective review of clinical experience at the University of Chicago, demonstrating the safety profile of 6-MP and azathioprine in children with IBD.

    Article  PubMed  CAS  Google Scholar 

  32. Hyams J, Markowitz J, Wyllie R: Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000, 137:192–196. A retrospective case series providing the first published data on the efficacy and safety of infliximab therapy in children with Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  33. Kugathasan S, Werlin SL, Martinez A, et al.: Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000, 95:3189–3194. An open-label, prospective clinical trial demonstrating the effects of infliximab in children and suggesting that the effects of anti-TNF therapy may be more long lasting if initiated early in the course of Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  34. Slonim AE, Bulone L, Damore MB, et al.: A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med 2000, 342:1633–1637.

    Article  PubMed  CAS  Google Scholar 

  35. Heuschkel RB, Menache CC, Megerian JT, Baird AE: Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 2000, 31:8–15. An important meta-analysis which establishes that enteral nutrition is as effective as corticosteroid therapy in inducing remission in children with active Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  36. Akobeng AK, Miller V, Stanton J, et al.: Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease. J Pediatr Gastroenterol Nutr 2000, 30:78–84.

    Article  PubMed  CAS  Google Scholar 

  37. Fell JME, Paintin M, Arnaud-Battandier F, et al.: Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther 2000, 14:281–289.

    Article  PubMed  CAS  Google Scholar 

  38. Falcone RA, Lewis LG, Warner BW: Predicting the need for colectomy in pediatric patients with ulcerative colitis. J Gastrointest Surg 2000, 4:201–206.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Gastroenterology and Nutrition, North Shore University Hospital, 300 Community Drive, 11030, Manhasset, NY, USA

    Cindy Haller MD & James Markowitz MD

Authors
  1. Cindy Haller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Markowitz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haller, C., Markowitz, J. A Perspective on inflammatory bowel disease in the child and adolescent at the turn of the millennium. Curr Gastroenterol Rep 3, 263–271 (2001). https://doi.org/10.1007/s11894-001-0031-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-001-0031-6

Keywords

Search

Navigation